Proteostasis Therapeutics, Inc. (NASDAQ:PTI)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.75 and last traded at $1.75, with a volume of 66,462 shares. The stock had previously closed at $1.84.

A number of research firms have recently commented on PTI. Leerink Swann restated an “outperform” rating and set a $9.00 price objective (down from $17.00) on shares of Proteostasis Therapeutics in a research note on Wednesday, August 16th. Zacks Investment Research downgraded shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, June 15th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Proteostasis Therapeutics in a research note on Friday, June 30th.

The firm’s market capitalization is $43.93 million. The company has a 50-day moving average price of $3.30 and a 200-day moving average price of $7.00.

Several large investors have recently bought and sold shares of PTI. FMR LLC increased its stake in Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after buying an additional 66,111 shares during the last quarter. Jennison Associates LLC increased its stake in Proteostasis Therapeutics by 6.2% in the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock valued at $9,713,000 after buying an additional 120,575 shares during the last quarter. Marshall Wace North America L.P. acquired a new stake in Proteostasis Therapeutics during the first quarter valued at approximately $5,946,000. MARSHALL WACE ASIA Ltd acquired a new stake in Proteostasis Therapeutics during the first quarter valued at approximately $5,946,000. Finally, HarbourVest Partners LLC acquired a new stake in Proteostasis Therapeutics during the first quarter valued at approximately $3,446,000. 75.40% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Proteostasis Therapeutics, Inc. (PTI) Hits New 1-Year Low at $1.75” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/22/proteostasis-therapeutics-inc-pti-hits-new-1-year-low-at-1-75.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.